The following is a summary of the MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript:

Financial Performance:

• MDxHealth reported a Q4 revenue of $19.4 million, a 50% increase compared to Q4 2022, and the full-year revenue was $70.2 million, an 89% increase year-over-year.

• Gross profit for Q4 was $12.7 million, a 75% increase from Q3 2022, with gross margins improving to 65.3% from 56% in Q4 2022. Similarly, for FY 2023, the gross profit was $43.9 million with an improved gross margin of 62.6%.

• The company managed to reduce its operating loss for Q4 to $6.3 million, a 30% reduction compared to the previous year, and the full-year operating loss was reduced 28% to $27.3 million.

• Cash equivalents by the end of 2023 were $22.4 million, and the company projects a revenue between $79 million and $81 million for 2024.

Business Progress:

• MDxHealth successfully expanded their test menu, establishing cross-selling of complementary diagnostic solutions, and broadened payer coverage.

• Over the last 18 months, the company grew its offering from one to four revenue-generating tests and all of their prostate cancer tests are now covered by Medicare.

• The company is considering various inbound opportunities for partnerships, mergers, acquisitions, and distribution.

• Additionally, the company plans to expand into the sector of patient monitoring for those on annual active surveillance with their Monitor project.

• The company will continue to focus on controlling costs, keeping operating expenses at bay while ensuring sustainable growth.

More details: MDxHealth IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.